851314-56-2

Basic information

• Product Name: 1-Benzyl-5,5-Difluoro-4-Oxo-Piperidine-3-Carboxylic Acid Ethyl Ester
• Synonyms: 1-Benzyl-5,5-Difluoro-4-Oxo-Piperidine-3-Carboxylic Acid Ethyl Ester;1-Benzyl-5,5-Difluoro-4-Oxo-Piperidine-3-Carboxylic Acid Ethyl Ester(WXFS0421)
• CAS NO: 851314-56-2
• Molecular Formula: C₁₅H₁₇F₂NO₃
• Molecular Weight: 297.2971864
• Mol File: 851314-56-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Benzyl-5,5-Difluoro-4-Oxo-Piperidine-3-Carboxylic Acid Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-5,5-Difluoro-4-Oxo-Piperidine-3-Carboxylic Acid Ethyl Ester(851314-56-2)
• EPA Substance Registry System: 1-Benzyl-5,5-Difluoro-4-Oxo-Piperidine-3-Carboxylic Acid Ethyl Ester(851314-56-2)

Safety Data

• Hazardous Substances Data: 851314-56-2(Hazardous Substances Data)

Usage

Molecular Weight

287.28 g/mol

Benzyl group

A phenyl group attached to a carbon atom in the molecule.

Piperidine ring

A six-membered nitrogen-containing ring structure.

Fluorine atoms

Two fluorine atoms present in the molecule.

Carboxylic acid group

A functional group consisting of a carbonyl (C=O) and a hydroxyl (-OH) group attached to the same carbon atom.

Ethyl ester functional group

An ester formed by the reaction of a carboxylic acid and an alcohol, in this case, ethyl alcohol.

Appearance

Likely a solid or oily liquid, depending on the conditions.

Solubility

Soluble in organic solvents like ethanol, methanol, and dichloromethane.

Reactivity

Can undergo reactions typical of esters, such as hydrolysis and transesterification.

Stability

Relatively stable under normal conditions, but sensitive to strong acids, bases, and nucleophiles.

Medicinal Chemistry

Potential use in the development of pharmaceutical drugs due to its unique structure and potential biological activity.

Organic Synthesis

Can be used as a building block for creating other complex compounds.

Hazards

Potential irritant or toxic, depending on the dose and exposure route.

Precautions

Handle in a well-ventilated area and use appropriate personal protective equipment (PPE), such as gloves and safety goggles.

Upstream product

• 23583-21-3 ethyl-3-benzylamino propionate 
• 851314-55-1 ethyl N-[3-(ethyloxy)-2,2-difluoro-3-oxopropyl]-N-(phenylmethyl)-beta-alaninate 
• 851314-54-0 ethyl N-(1H-1,2,3-benzotriazol-1-ylmethyl)-N-(phenylmethyl)-beta-alaninate 

Downstream Products

• 851314-41-5 1-benzyl-5,5-difluoro-4-trifluoromethanesulfonyloxy-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid ethyl ester 
• 1067914-81-1 3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol 
• 1233932-22-3 8-benzyl-6,6-difluoro-4-(phenylsulfonyl)-1-oxa-4,8-diazaspiro[4.5]decane 
• 1233932-23-4 6,6-difluoro-4-(phenylsulfonyl)-1-oxa-4,8-diazaspiro[4.5]decane 
• 1233929-29-7 6,6-difluoro-N-phenyl-4-(phenylsulfonyl)-1-oxa-4,8-diazaspiro[4.5]decane-8-carboxamide 
• 1209780-71-1 tert-butyl 3,3-difluoro-4-hydroxy-piperidine-1-carboxylate 
• 1239596-54-3 3,3-difluoropiperidin-4-ol 
• 1202647-35-5 C₃₃H₃₃ClF₄N₂O₃ 
• 851314-31-3 C₃₆H₃₅Cl₃F₄N₂O₄ 
• 851314-26-6 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide 
• 851314-50-6 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 851314-44-8 1-benzyl-4-{4-[3-(tert-butyldimethylsilanyloxy)propyl]phenyl}-5,5-difluoro-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid ethyl ester 
• 851314-47-1 5,5-difluoro-4-[4-(3-hydroxypropyl)phenyl]-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 1039741-54-2 1-benzyl-3,3-difluoropiperidin-4-one 

Relevant articles and documents

5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER

The present invention discloses 5-substituted difluoropiperidine compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The 5-substituted difluoropiperidine compounds, derivatives

SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY

The present invention discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The quinazoline compounds, derivatives and pharmaceutically acceptabl

Quinazoline derivative salt-type crystal forms and preparation method and application thereof

The invention discloses quinazoline derivative salt-type crystal forms and a preparation method and application thereof. The quinazoline derivative salt-type crystal forms are specifically the hydrochloride crystal forms A, B, C, D, F, H, I, the sulphate

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists

To generate novel human Orexin-2 Receptor (OX2R) antagonists, a spiropiperidine based scaffold was designed and a SAR study was carried out. Compound 4f possessed the highest OX2R antagonistic activity with an IC 50 value of 3 nM with 450-fold selectivity against Orexin-1 Receptor (OX1R).

New classes of potent and bioavailable human renin inhibitors

New classes of de novo designed renin inhibitors are reported. Some of these compounds display excellent in vitro and in vivo activities toward human renin in a TGR model. The synthesis of these new types of mono- and bicyclic scaffolds are reported, and properties of selected compounds discussed.